Press release -
New ADHD Medication in Norway
Oslo, 14.01.2026 – FrostPharma today announces that Silarosa (lisdexamfetamine oral solution) is now available in Norway. The medication offers a personalized treatment option for children and adolescents with ADHD who have difficulty swallowing tablets or capsules.
Nordic researchers recently published a review article in Acta Paediatricashowing that between 15–37% of all oral medication administered to children as tablets or capsules require some form of manipulation due to the lack of age-appropriate formulations. Common manipulations include tablet splitting, crushing or dispersing, often resulting in dose inaccuracies, variable solubility and inconsistent pharmacokinetics. Studies show manipulation can lead to dosing errors with potential harm. (5)
“At FrostPharma, we are driven by a strong commitment to make a difference. Our journey has always been about listening to healthcare professionals, understanding their challenges, and acting quickly to close gaps that affect both patients and healthcare providers. We are therefore pleased to announce that Silarosa (lisdexamfetamine) 10 mg/ml oral solution has been approved by the Norwegian Medicines Agency and is now available by prescription in Norway,” says Magnus Nylèn, CEO of FrostPharma.
Silarosa 10 mg/ml is an oral solution of lisdexamfetamine that offers an alternative treatment for children and adolescents with ADHD. It enables personalized treatment for children aged six years and older with hyperkinetic disorders (ADHD), when the response to previous methylphenidate treatment is considered clinically insufficient. Regulatory authorities view the availability of multiple formulations for children and adolescents as a positive development. (4)
About FrostPharma
FrostPharma is a fast-growing pharmaceutical company with its heart in the Nordics. Since our establishment in 2017, we have introduced a wide range of value-adding medicines across several therapeutic areas. Through close collaboration with the healthcare sector, FrostPharma identifies, develops, and delivers medicines that make a difference—for patients, for healthcare professionals, and for society as a whole.
ID 13187653 01/2026 Press Release Silarosa NO
Contact
Magnus Nylèn, CEO
📧 magnus.nylen@frostpharma.com
Rebecka Grund, COO
📧 rebecka.grund@frostpharma.com
🌐 www.frostpharma.se
📍 Berga Backe 2, 182 53 Danderyd, Sweden
📞 +46 (0) 8 24 36 60
References
Topics
Categories
FrostPharma är ett snabbväxande läkemedelsbolag med hjärtat i Norden. Sedan starten 2017 har FrostPharma tillgängliggjort ett stort antal värdeskapande läkemedel i ett antal olika sjukdomsområden. Genom nära samarbete med hälso- och sjukvården identifierar, utvecklar och tillhandahåller Frostpharma läkemedel som gör skillnad – för patienter, för vården och för samhället i stort.
